Starpharma after 22 years, page-6

well @col69

Stop being a bully please
It would be much appreciated

Below is a graphic of how the voting went


There was approximately 55-58% of share holder base that voted yes/no on the remuneration question



It is obviously the institutions holding around 51.4% (209,299,625 shares) of the company who voted for the resolutions



The balance is made up of share registry is comprised of the following

general public 42.3% (172,465,186 shares) , WHO VERY RARELY BOTHER TO VOTE UNLESS LOBBIED.

individual insiders 3.4% (13,909,225 shares) , WHO WOULD VOTE FOR THE RESOLUTIONS

private companies 2.5% (10,321,580 shares) and WHO WOULD MOST PROBABLY VOTE. I CERTAINLY DID

government 0.4% (1,448,798 shares). WHO MOST PROBABLY VOTE FOR THE RESOLUTIONS OR NOT GIVE A STUFF


"I am guessing the fan club will vote yes yet again for their remuneration at the 2022 AGM"
SO BASED ON YOUR ABOVE STATEMENT WOULD YOU BE REFERRING TO THE INSTITUTIONS WHO VOTED IN FAVOUR OF ALL THE RESOLUTIONS LAST YEAR

or most of the general public that did not bother to vote



it's plain to see....... it was not the retail shareholders...........who most probably are not proactive (in other words do not give a rats)


In regards to your quote

expecting DEP results by 30 June as touted by the company themselves


please do not make up things to suit your agenda



BELOW IS A DIRECT QUOTE FROM JACKIE FAIRLEY IN REGARDS TO READ OUT OF THREE DEP DRUGS IN PHASE 2 TRIALS AND COMPLETION WORD FOR WORD


AND I QUOTE


"Our expectations in terms of timing of these


our expectations is for all three of these phase *3 products to be completing and reading out in calendar year 2022

*And I would expect that the first half would include dep docetaxel and the prostate component of dep cabazitaxel*

and I am going to talk about ovarian and oesophageal cancer in dep cabazitaxel in a moment because we've seen some excellent results there and would be likely to be in the second half

and dep irinotecan more likely to be in the second half of calendar 2022"


Unquote

So never has she stated the words will
Nevertheless I hope readouts will occur around this time frame


On another note

I was very happy to see the progression of all of the AZD0466 trials. I understand there are is now recruiting in 10 additional sites for all the trials and an expansion of additional 15  locations (formally 10 now expanded to 25) in the NHL trial and an additional 3 locations in the AZD0466 combination study

THIS BRINGS ONLINE AN ADDITIONAL 13 LOCATIONS FOR THE 2 TRIALS SO FAR







My understanding of timelines so far

Dep Docetaxel
Dep Cabazitaxel
Dep Irinotecan

Completion and data readout this calendar year

AZD0466 entering phase 2 this calendar year (and subsequent milestone payments)

Dep Gembitabine entering FIHT imminently

Radiotherapeutic partnership signed with big pharma this calendar year

TGA approves Viraleze into Australia imminently

Starpharma sacks Mundipharma or something massive is planned in marketing Vivagel. Mundipharma go all out and spend a few million promoting product this calendar year

FDA NDA approval is granted finally this calendar year or the study that was put on hold is initiated in the USA

Another indication for AZD0466 is put into clinical trials sometime this calendar year

An ADC trial or multiple trials in FIHT's are initiated this calendar year

Several more new partnerships are announced with big pharma this calendar year

There is a lot more.......


Oh and finally the share price goes above it's historical high

The above in reference to timelines is my opinion

DYOR